Effects of genetic polymorphisms on metabolic kinetics, pharmacodynamics and adverse reactions of amitriptyline

doi:10.12092/j.issn.1009-2501.2019.02.019

Abstract

Abstract:

Amitriptyline is a tricyclic antidepressant for the treatment of severe depression, post-traumatic stress disorder and other psychiatric diseases, which is widely used in clinical application. However, there are significant individual differences in the response of amitriptyline. Research has shown that genetics polymorphisms of CYP2D6, CYP2C19 and ABCB1 have certain effects on the pharmacokinetics (PK), pharmacodynamics (PD) and adverse reactions (ADR) of amitriptyline. In this paper, we have drawn a preliminary conclusion by comparing the effects of CYP2D6 and CYP2C19 gene polymorphisms on amitriptyline PK, PD and ADR. For CYP2C19 ultrarapid metabolizers or extensive metabolizers, the genetic polymorphism of CYP2D6 has a greater effect on the overall metabolism of amitriptyline. However, for CYP2C19 poor metabolizers, the genetic polymorphisms of CYP2C19 have greater influence. Hopefully, this article can provide genetic-based advice and assistance for the individualized administration of amitriptyline.

Key words: amitriptyline, gene polymorphism, CYP2C19, CYP2D6, ABCB1

CLC Number:

R969.1
R971

WANG Ente, ZHANG Xiaodan, ZHOU Shuang, ZHAO Xia, ZHOU Ying, CUI Yimin. Effects of genetic polymorphisms on metabolic kinetics, pharmacodynamics and adverse reactions of amitriptyline[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 235-240.

References

［1］徐象威, 陈银巧, 朱佩祯. 阿米替林联合阿片类药物治疗中重度癌痛伴抑郁患者疗效分析［J］. 中国临床药理学与治疗学, 2017, 22(10): 1145-1151.
［2］郑安海, 周冀英. 阿米替林预防性治疗偏头痛的研究进展［J］. 重庆医学, 2013, 42(24): 2925-2928.
［3］薛庆峰, 杨天德. 阿米替林在治疗神经病理性疼痛中作用机制研究和进展［J］. 国际麻醉学与复苏杂志, 2011, (3): 362-365.
［4］曾丽娟, 黄叶盛, 龚晓兵. 多潘立酮联合阿米替林治疗功能性消化不良的meta分析［J］. 内科, 2014, 9(6): 652-655.
［5］Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update［J］. Clin Pharmacol Ther，2017, 102(1): 37-44.
［6］Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants［J］. Cell Mol Neurobiol, 1999, 19(3): 373-409.
［7］PGx gene-specific information tables for CYP2C19. ［EB/OL］.https://www. pharmgkb.org/page/cyp2c19RefMaterials>. Accessed November 20 2018.
［8］张爱玲, 胡欣, 杨莉萍. 亚洲健康人群CYP2C19基因型发生率的合并分析［J］. 中国循证医学杂志, 2014, 14(4): 427-434.
［9］Steimer W, Zopf K, von Amelunxen S, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers［J］. Clin Chem, 2004, 50(9): 1623-1633.
［10］陈丽霞, 王志纲, 爱民. 抑郁症患者细胞色素P4502C19基因型对阿米替林血药浓度及其去甲基代谢的影响［J］. 中国神经精神疾病杂志, 2005, (1): 33-36.
［11］de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients［J］. Pharmacogenomics J, 2011, 11(5): 359-367.
［12］Halling J, Weihe P, Brosen K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population［J］. Br J Clin Pharmacol, 2008, 65(1): 134-138.
［13］Steimer W, Zopf K, von Amelunxen S, et al. Amitriptyline or not, that is the question: pharmacogenetics testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy［J］. Clin Chem, 2005, 51(2): 376-385.
［14］Hodgson K, Tansey K, Dernovsek MZ, et al. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response［J］. J Psychopharmacol, 2014, 28(2): 133-141.
［15］Morita S, Shimoda K, Someya T, et al. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline［J］. J Clin Psychopharmacol, 2000, 20(2): 141-9.
［16］Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte--an update of guidelines［J］. Clin Pharmacol Ther, 2011, 89(5): 662-73.
［17］Ryu S, Park S, Lee JH, et al. A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans［J］. Clin Transl Sci, 2017, 10(2): 93-101.
［18］Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response［J］. J Clin Psychopharmacol, 1994, 14(4): 230-240.
［19］Abaut AY, Chevanne F, Le Corre P. Oral bioavailability and intestinal secretion of amitriptyline: Role of P-glycoprotein ［J］ ? Int J Pharm, 2007, 330(1-2):121-128.
［20］Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression［J］. Neuron, 2008, 57(2): 203-209.
［21］Leschziner GD, Andrew T, Pirmohamed M, et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research［J］. Pharmacogenomics J, 2007, 7(3): 154-179.
［22］Roberts RL, Joyce PR, Mulder RT, et al. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression［J］. Pharmacogenomics J, 2002, 2(3):191-196.
［23］Jensen BP, Roberts RL, Vyas R, et al. Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers［J］. Br J Clin Pharmacol, 2012, 73(4): 619-628.

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[4]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[5]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[6]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[7]	WANG Chunling, ZHOU Renjing, FENG Rui, WU Yanneng. Effect of adiponectin 45 T/G gene polymorphism on type 2 diabetes treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 312-317.
[8]	XIA Chunyong, ZHANG Zuowen, HE Xiaoyan, LIU Jie, LI Xiaoya, CHANG Qiuhong, QIN Lijuan, CAO Zhenming, DING Ling. Correlation between CYP2C19 gene polymorphism and individualized medication in patients with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 318-323.
[9]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[10]	YANG Chunyan, ZHANG Wen, WANG Peipei, PENG Jing, JIANG Jia, SONG Jing, LIU Jun, LI Yueran, YANG Kui, WANG Sheng, XU Zhenyu, LUAN Jiajie. Distribution of gene polymorphism in folate metabolism pathway and its effect on serumhomocysteine concentration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1259-1264.
[11]	. Research Progress of Pharmacogenomics of Dabigatran Etexilate and Rivaroxaban [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1200-1207.
[12]	WANG Fengling, MENG Xiangyun, CHEN Zhengxu, CAO Rongjuan, HE Zhengmin, YE Xi, WANG Cong, LI Qi. Analysis on genetic polymorphism of SLCO1B1 and ApoE in patients with cardiovascular diseases of Han nationality in Anhui area and its clinical significance for individualized use of statins [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 40-48.
[13]	XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang. Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.
[14]	PENG Jing, LIU Jun, XU Huifang, LI Yueran, JIANG Jia, WANG Sheng, ZHOU Dexi, ZHU Yanhong, YANG Kui, LUAN Jiajie. Correlation study between cytochrome P4502C19 gene polymorphism or metabolic type and ADP induced-platelet aggregation inhibition and clopidogrel resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 746-751.
[15]	TANG Mufei, SHEN Yunzhu, ZHANG Baoguo. Influence of CYP2D6 gene polymorphism on the effect of tropisetron in preventing chemotherapy induced nausea and vomiting [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 817-822.